bluebird bio (BLUE) announced that it had received European approval for its gene therapy Zynteglo to treat patients with beta-thalassemia. This was the first approval for the biotech which was an important milestone to reach. However, this is only the beginning. That's because bluebird bio expects to possibly file for approval of Zynteglo to the FDA by the end of this year. That would set up a potential U.S. approval for the gene therapy in 2020 for the very same indication.
Approval Based On Promising Data
The European Union approved Zynteglo to treat